Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson's disease
Objective. Health economic expertise of pramipexole extended release monotherapy at early stages of Parkinson's disease. Methods. An economic model was developed based on clinical studies to derive comparative information on the effectiveness, utility and direct medical costs of antiparkinsonia...
Saved in:
Main Authors: | D. Yu. Belousov (Author), E. V. Afanasyeva (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
by: Faddoul L, et al.
Published: (2018) -
Comparative pharmacoeconomical analysis of modern antidepressants in monotherapy
by: A. E. Cheberda, et al.
Published: (2018) -
Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in Taiwan
by: K. Arnold Chan, et al.
Published: (2020) -
Pharmacoeconomic analysis of Movalis in patients with osteoarthritis and rheumatoid arthritis
by: E. S. Tsvetkova, et al.
Published: (2018) -
Pharmacoeconomic analysis of perampanel for resistance partial epilepsy
by: D. Yu. Belousov, et al.
Published: (2018)